Device Breakdown

T-REM3DIE is an innovative system for tendon repair, biocompatible, biodegradable, easily implantable, minimally invasive and capable of transforming tendon tissue injuries from permanent disability to temporary discomfort, ensuring positive patient follow-ups.

Aiming to help​, our purpose is to satisfy the clinical need in tendon and ligament repair by helping people to completely restore movement capability.

The Technology

Biocompatible and resorbable devices for the repair of tendons and ligaments.

Functional

Ensure an adequate response under physiological loads allowing rehabilitation to begin a few days after surgery​.

Sutureless & Knotless

Prevents any danger or malfunction as adhesions, slipping, knot failure and gap formation​.

Biodegradable

Made of medical grade polymers of controlled degradation, that deliver safety and quality​.

Easy to apply

The T-RESAP applicator perfectly coupled with the device, allows a quick, low-profile and reproducible application​.

Why IT MATTERS?

Innovative devices for tendons and ligaments repair made of medical-grade materials.

BIODEGRADABLE

Specific polymers with controlled degradation

EASY TO APPLY

Thanks to the T-RESAP applicator that allows a quick, low-profile and reproducible application

PHYSIOLOGICAL LOAD TRANSMISSION

Our technology has been designed to re-create the physiological load on the tissue.

THE CONTEXT

Nowadays, the limitations of current tendon and ligament repair techniques frequently result in a partial restoration of the physiological tissue’s properties and joint movement. The primary method for tendon repair is surgical suture, which employs different techniques that have been developed during the past years. The two main issues associated with the use of tendon sutures are the suture rupture itself, the development of high stresses at the interface between the suture and the tendon, and adhesions with the surrounding tissues. Other technologies available on the market regard devices that are not bioresorbable or percutaneous suture, nor biodegradable for tendon and ligament repair. Issues that arise some complications, such as a permanent reduction in the mobility of the affected joint.​

In this context, the T-REM3DIE (Tendon REpair MEdical DevIcE) initiative was created in response to a clinical need identified by Dr. Federica Bergamin, an orthopaedic surgeon at Ivrea Hospital – ASLTO4. T-REM3DIE is an implantable, biodegradable medical device. Its peculiar and innovative geometry allows to overcome all the issues related with the use of current tendon repair techniques (traditional sutures and other medical devices).​

Tendon injuries represent a considerable economic and social burden for both the healthcare system and patients involved. Tendon repair remains a challenge despite the important advances in surgical techniques, and protocols of post-operative rehabilitation. Hand, Achilles and Rotator cuff tendons are the most prevalent injuries worldwide. ​The patent allows the protection of the device configuration for Achilles and hand flexor tendons repair. According to the Hospital Discharge Register (HDR) data, for Italy alone in 2019 there were around 6000 Achilles tendon ruptures.

However, considering the medical literature the incidence rate is 23.3/100 000 injuries forr habitat. ​Instead, there were around 9000 open wounds cases for hand and wrist with tendon involvement in 2019 (HDR Italy). Furthermore, the Italian representative of the SINIACA-IDB (S-IDB) reported 20568 cases per year of hand flexor rupture or laceration in the Italian emergency departments. From the information collected, the addressable market for the application on Achilles tendon is estimated between 6000 and 12000 cases per year and between 9000 and 20568 cases per year for hand flexor tendon.​

To commercialize a medical device in the European and American countries some certifications are required to obtain CE Mark and FDA Mark before the market entry. T-REM3DIE is a class III medical device, which is subjected to the most stringent requirement. T-RESAP system, instead, is a class I medical device, and it does not require a clinical evaluation study. Further crucial activities are related to the device manufacturing and its commercialization. In particular: the device and applicator manufacturing including packaging and final sterilization will be outsourced to a manufacturing company. The biomedical material to make the devices will be acquired from a leading industry in the market.

The market entry strategy in Europe and Worldwide will be based on the involvement of distributors of medical devices allowing the commercialization. Moreover, the T-REM3DIE adoption could be facilitated through the support of the opinion leaders who will be involved during the device’s clinical trials phase. The clinical adoption of the T-REM3DIE will increase the outcome of the surgery allowing an early return to daily-life activities. And moreover, reduces the economic burden on the National Health System and the patient.​

Scroll to Top